A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Clinical trial NCT02841748 · COMPLETED

Trial details

NCT number: NCT02841748
Sponsor: University of Chicago
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Cancer Squamous Cell Carcinoma of the Head and Neck

Start date: 2017-05-10
Primary completion: 2025-02-11
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.